Rapid Improvement of Dilated Cardiomyopathy With Anakinra

Share this content:
Rapid Improvement of Dilated Cardiomyopathy With Anakinra
Rapid Improvement of Dilated Cardiomyopathy With Anakinra

TUESDAY, July 31, 2018 (HealthDay News) -- In a report published online July 31 in the Annals of Internal Medicine, doctors describe the case of a patient with dilated cardiomyopathy who experienced rapid clinical improvements with use of anakinra, the recombinant form of the endogenous antagonist for the interleukin-1 receptor.

Giacomo De Luca, M.D., from the Vita-Salute San Raffaele University in Milan, and colleagues present the case of a 57-year-old man with a two-year history of dilated cardiomyopathy who was hospitalized for chronic fatigue and dyspnea, which was secondary to New York Heart Association class III heart failure.

The researchers note that the patient was initially treated with diuretics, β-blockers, and angiotensin-converting enzyme inhibitors. Six months later, when he was still symptomatic, the patient was determined to have met the criteria for idiopathic inflammatory dilated cardiomyopathy, and initiated treatment with anakinra. Within two weeks, the patient's clinical symptoms related to heart failure had improved markedly, to New York Heart Association class I. An increase in the left ventricular ejection fraction was revealed on transthoracic echocardiography, and troponin T and N-terminal pro-B type natriuretic peptide levels normalized.

"Because of our experience and what is already known about anakinra, we believe that this treatment and the role of chronic low-grade inflammation in dilated cardiomyopathy deserve further investigation," the authors write.

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Moves to Restrict Flavored E-Cig Sales, Ban Menthol Cigarettes

FDA Moves to Restrict Flavored E-Cig Sales, Ban ...

The move stops short of the full ban on e-cigarettes that had been expected

Name-Brand Medications Driving Spike in U.S. Drug Spending

Name-Brand Medications Driving Spike in U.S. Drug Spending

Greatest costs for Humira, Remicade, Enbrel, Novolog, and Neulasta

is free, fast, and customized just for you!




Already a member?

Sign In Now »